Routine share withholding; mechanical by default.
Loading…
Traded Dec 17, 2025 · Filed Dec 18, 2025
Incyte's Head of Tech. Operations sold $420K of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$420,455
Shares × reported transaction price
50 days after results of Oct 28, 2025, 55 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $97.63 on Dec 17, 2025, 77% above its 52-week low and 10% below its high, after a 5% drop over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 80% of the way up, from 250 adjusted closes. 30 trading days earlier: $102.92 on Nov 4, 2025. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, the same day as this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.5% | +1.4% | -3.9% |
| 30 days | -0.1% | -0.4% | +0.4% |
| 90 days | -9.5% | -3.0% | -6.4% |
| 180 days | -3.6% | +8.9% | -12.5% |
Past results only. Not a forecast.
Routine share withholding; mechanical by default.
Officer sold ~$1.18M of Incyte
Automatic saleOfficer sold ~$1.59M of Incyte
Automatic sale